This page shows the latest Xospata news and features for those working in and with pharma, biotech and healthcare.
However, following further discussions with Astellas, NICE has recommended Xospata monotherapy for treating adult patients with relapsed or refractory FLT3-positive AML. ... home. It also acknowledged that the clinical evidence demonstrates that those
Xospata. Also receiving a no from NICE was Astellas, which received a rejection of its FLT3-inhibitor Xospata(gilteritinib). ... Xospata was also too costly for the usual NICE recommendation, with a list price of £14, 188 per 28-day pack.
The results of that study showed Xospata extended overall survival (OS) to 9.3 months from 5.6 months in the control group. ... Xospata is the first FLT3 inhibitor to be approved for use in relapsed or refractory AML with a FLT3 inhibitor mutation.
Xospata (gilteritinib), setting up a likely approval in the EU in the near future. ... The decision is based on the results from Astellas’ phase 3 ADMIRAL trial investigating Xospata compared to salvage chemotherapy.
positive relapsed AML – Xospata (gilteritinib) – which picked up an FDA approval in this setting last November and was launched in Japan last December. ... Xospata is starting to bring in its first revenues – adding 2.5bn yen ($22m) to Astellas’
Xospata offers new hope to patients for whom the treatment path forward is unclear,” said Steven Benner, senior vice president and global therapeutic area head, Oncology Development, Astellas. ... Like Xospata, these are both being tested initially in
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...